What is it about?
Giant intracranial meningiomas are challenging because of surgical experience, tumor size, peritumoral edema, blood supply, anatomical changes, and limited visibility. This study analyzed a series of surgically treated consecutive intra-cranial giant meningiomas, and the factors influencing the surgical outcome were investigated.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Meningiomas are the most common central nervous system tumors and most of them are WHO Grade 1 tumors. However, even if they are WHO Grade 1, giant meningiomas have a high risk of recurrence and mortality. We observed two statistically significant results. Firstly, increased tumor sizes and high tumor WHO grades have negative impacts on tumor recurrence. Secondly, the mortality rate of patients with tumor recurrence is higher than that of patients without.
Perspectives
Meningiomas should be treated with a multidisciplinary approach and monitored regularly. Some meningiomas can show multiple recurrences. Future developments at the molecular level will increase success in meningioma treatment.
Professor Tayfun Hakan
University of Health Sciences, İstanbul
Read the Original
This page is a summary of: Recurrence and Mortality Rate in a 42 Patient Cohort of Giant Meningiomas, World Neurosurgery, June 2024, Elsevier,
DOI: 10.1016/j.wneu.2024.03.133.
You can read the full text:
Contributors
The following have contributed to this page
